Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Show other versions (1)

<p><strong>Background:</strong> We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.</p> <p><strong>Methods:</strong> This randomised, controlled, open-label, plat...

Full description

Bibliographic Details
Main Authors:	RECOVERY Collaborative Group, Horby, P, Emberson, J, Mafham, M, Peto, L, Campbell, M, Pessoa-Amorim, G, Spata, E, Staplin, N, Day, J, Juszczak, E, Knight, M, Haynes, R, Landray, M
Format:	Journal article
Language:	English
Published:	Elsevier 2022

Similar Items

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Mafham, M, et al.
Published: (2021)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Landray, M, et al.
Published: (2022)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, P, et al.
Published: (2021)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
by: RECOVERY Collaborative Group, et al.
Published: (2022)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, P, et al.
Published: (2024)

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
by: Haynes, R, et al.
Published: (2023)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, PW, et al.
Published: (2023)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, PW, et al.
Published: (2021)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Abani, O, et al.
Published: (2023)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group, et al.
Published: (2021)

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, PW, et al.
Published: (2021)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group, et al.
Published: (2024-01-01)

Dexamethasone in hospitalized patients with Covid-19 — preliminary report
by: Horby, P, et al.
Published: (2020)

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group
Published: (2021)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group
Published: (2020)

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group, et al.
Published: (2024)

Allocated but not treated: the silent 16% – Authors' reply
by: Horby, P, et al.
Published: (2022)

Effect of hydroxychloroquine in hospitalized patients with COVID-19
by: Horby, P, et al.
Published: (2020)

Making trials part of good clinical care: lessons from the RECOVERY trial
by: Pessoa-Amorim, G, et al.
Published: (2021)

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group
Published: (2024)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
by: Emberson, JR, et al.
Published: (2010)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
by: Reith, C, et al.
Published: (2017)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
by: Mafham, M, et al.
Published: (2011)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
by: C. Reith, et al.
Published: (2017-05-01)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
by: Shankar-Hari, M, et al.
Published: (2021)

Establishing COVID-19 trials at scale and pace: experience from the RECOVERY trial
by: Peto, L, et al.
Published: (2022)

In practice: RECOVERY Trial
by: Horby, P, et al.
Published: (2024)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
by: Zhu, P, et al.
Published: (2020)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
by: Mafham, M, et al.
Published: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
by: Harper, C, et al.
Published: (2021)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
by: Harper, C, et al.
Published: (2023)

Baricitinib for alopecia areata
by: Hamza Imran, et al.
Published: (2023-04-01)

Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022-03-01)

Efficacy of baricitinib in severe coronavirus disease 2019
by: Ahmed M A E F Amer, et al.
Published: (2023-01-01)

Facilitating participation in clinical trials during pregnancy
by: Vousden, N, et al.
Published: (2023)

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England
by: Pessoa-Amorim, G, et al.
Published: (2024)